BTIG analyst David Larsen lowered the firm’s price target on Health Catalyst (HCAT) to $10 from $13 and keeps a Buy rating on the shares after its Q4 earnings miss. The firm sees the company “continuing to grind” as its management indicated that the end-market is continuing to improve with hospital margins approaching pre-pandemic levels, but its reduced price target reflects near-term lumpiness in gross margins, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst’s Promising Financial Trajectory and Growth Potential Justifies Buy Rating
- Health Catalyst’s Strategic Growth and Robust Technology Segment Drive Buy Rating
- Health Catalyst Reports Strong 2024 Financial Performance
- Health Catalyst reports Q4 EPS 4c, consensus 8c
- Health Catalyst Announces Board Changes Amid Strong Growth